Anti-LAT3/ SLC43A1/ PB39 monoclonal antibody

Anti-LAT3/ SLC43A1/ PB39 antibody for FACS & in-vivo assay

Target products collectionGo to SLC43A1/SLC43A1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1624-Ab-1/ GM-Tg-hg-MP1624-Ab-2Anti-Human SLC43A1 monoclonal antibodyHuman
GM-Tg-rg-MP1624-Ab-1/ GM-Tg-rg-MP1624-Ab-2Anti-Rat SLC43A1 monoclonal antibodyRat
GM-Tg-mg-MP1624-Ab-1/ GM-Tg-mg-MP1624-Ab-2Anti-Mouse SLC43A1 monoclonal antibodyMouse
GM-Tg-cynog-MP1624-Ab-1/ GM-Tg-cynog-MP1624-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC43A1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1624-Ab-1/ GM-Tg-felg-MP1624-Ab-2Anti-Feline SLC43A1 monoclonal antibodyFeline
GM-Tg-cang-MP1624-Ab-1/ GM-Tg-cang-MP1624-Ab-2Anti-Canine SLC43A1 monoclonal antibodyCanine
GM-Tg-bovg-MP1624-Ab-1/ GM-Tg-bovg-MP1624-Ab-2Anti-Bovine SLC43A1 monoclonal antibodyBovine
GM-Tg-equg-MP1624-Ab-1/ GM-Tg-equg-MP1624-Ab-2Anti-Equine SLC43A1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1624-Ab-1/ GM-Tg-hg-MP1624-Ab-2; GM-Tg-rg-MP1624-Ab-1/ GM-Tg-rg-MP1624-Ab-2;
GM-Tg-mg-MP1624-Ab-1/ GM-Tg-mg-MP1624-Ab-2; GM-Tg-cynog-MP1624-Ab-1/ GM-Tg-cynog-MP1624-Ab-2;
GM-Tg-felg-MP1624-Ab-1/ GM-Tg-felg-MP1624-Ab-2; GM-Tg-cang-MP1624-Ab-1/ GM-Tg-cang-MP1624-Ab-2;
GM-Tg-bovg-MP1624-Ab-1/ GM-Tg-bovg-MP1624-Ab-2; GM-Tg-equg-MP1624-Ab-1/ GM-Tg-equg-MP1624-Ab-2
Products NameAnti-SLC43A1 monoclonal antibody
Formatmab
Target NameSLC43A1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SLC43A1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LAT3/ SLC43A1/ PB39 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1624
    Target NameSLC43A1
    Gene ID8501,72401,311168,706053,483493,101087424,614153,100066449
    Gene Symbol and Synonyms2610016F07Rik,LAT3,PB39,POV1,R00504,SLC43A1
    Uniprot AccessionO75387
    Uniprot Entry NameLAT3_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseCancer
    Gene EnsemblENSG00000149150
    Target ClassificationTumor-associated antigen (TAA)

    The target: SLC43A1, gene name: SLC43A1, also named as LAT3, PB39, POV1, R00504. SLC43A1 belongs to the system L family of plasma membrane carrier proteins that transports large neutral amino acids (Babu et al., 2003 [PubMed 12930836]).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.